NMDA Antagonists in Bipolar Depression

Trial Profile

NMDA Antagonists in Bipolar Depression

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Cycloserine (Primary) ; Ketamine (Primary) ; Lurasidone; Olanzapine/fluoxetine; Quetiapine
  • Indications Bipolar depression; Bipolar I disorders; Bipolar II disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Apr 2016 Safety and tolerability of ketamine and d-cycloserine removed from primary endpoint ; hence trial focus changed from TU + AR to TU.
    • 25 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 29 Sep 2015 Planned End Date changed from 1 Sep 2015 to 1 Dec 2015 as per ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top